Please assess the completion status of the following clinical trial:

Trial Title: Polycystic Ovary Syndrome and Liraglutide as Add-on Therapy on Metformin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years old to menopause~* polycystic ovary syndrome (NICHD criteria)~* BMI of 30 kg/m² or higher~* poor response to previous treatment with metformin for at least 3 months~Exclusion Criteria:~* type 1 or type 2 diabetes mellitus~* history of carcinoma~* Cushing's syndrome or congenital (non-classic) adrenal hyperplasia~* personal or family history of MEN 2~* significant cardiovascular, kidney or hepatic disease~* the use of medications known or suspected to affect reproductive or metabolic functions~* the use of statins, within 90 days prior to study entry

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- metformin (Type: ACTIVE_COMPARATOR): In the metformin group metformin was initiated at a dose of 500 mg once per day and increased by 500 mg every 3 days up to 1000 mg BID per os.
- liraglutide (Type: ACTIVE_COMPARATOR): In the liraglutide group liraglutide was initiated at a dose of 0.6 mg injected sc once per day and increased to 1.2 mg/day after 1 week.
- metformin and liraglutide (Type: ACTIVE_COMPARATOR): In the metformin and liraglutide group metformin was initiated at a dose of 500 mg once per day and increased by 500 mg every 3 days up to 1000 mg BID per os. At the same time liraglutide was initiated at a dose of 0.6 mg injected sc once per day and increased to 1.2 mg/day after 1 week.

Based on this trial design, predict the completion outcome and termination type (if applicable).